On August 11, MGI and Chigene officially signed a strategic cooperation agreement to advance precision diagnosis using whole genome sequencing (WGS). The partnership combines MGI’s high-throughput DNBSEQ-T7 sequencing platform with Chigene’s big data analysis and storage capabilities, enabling faster, more accurate genomic insights.
Transforming Molecular Diagnosis
Whole genome sequencing provides a complete view of the genome, supporting research and clinical applications that were once limited by high costs. MGI has consistently driven innovation to make sequencing technology more accessible, helping to reduce costs and expand the reach of precision medicine.
DNBSEQ-T7: High-throughput Sequencing Innovation
MGI’s DNBSEQ-T7 platform delivers ultra-high throughput and flexibility, generating up to 6Tb of data per day and completing up to 60 whole human genomes daily. Its speed and scalability make personal whole genome sequencing more affordable, supporting a broader adoption of WGS in clinical and research settings.
Chigene’s Big Data Expertise
Chigene has been a leader in genetic big data and precision medicine, building databases of hundreds of thousands of patient genomes and using AI-assisted platforms for rapid diagnosis of thousands of genetic diseases. Integrating MGI’s sequencing technology allows Chigene to further enhance its genomic analysis capabilities and support scientific discoveries globally.
A Shared Vision for Accessible Genomics
MGI is committed to delivering core tools and technologies that advance life sciences through intelligent innovation. By combining MGI’s sequencing platform with Chigene’s analytical expertise, the partnership aims to make WGS more accessible, drive breakthroughs in precision diagnosis, and accelerate the adoption of genomics for research and clinical applications worldwide.
